ERCC在骨肉瘤发病机制作用与顺铂耐药性

Role of ERCC in the pathogenesis of osteosarcoma and cisplatin resistance

骨肉瘤是一种好发于青少年的恶性骨肿瘤,它的转移能力较强并且预后较差,有研究表明骨肉瘤的发生及对顺铂耐药均与ERCC基因相关.ERCC基因作为核苷酸切除修复途径的关键组成基因,可影响DNA修复能力.其功能差异主要与单核苷酸多态性相关,低表达可能会造成骨肉瘤发病风险升高,高表达则使患者对顺铂耐药性增加.此外,ERCC基因对骨肉瘤的发病与预后及指导化疗药物的选择有重要意义.对ERCC基因的靶向抑制为减少顺铂的耐药性提供了可能.本文综述了ER-CC在骨肉瘤中的相关研究进展,为进一步临床转化应用提供相关思路.

Osteosarcoma,a kind of malignant bone tumor that often occurs in adolescents,has a strong metastatic capacity and poor prognosis.The occurrence of osteosarcoma and its resistance to cisplatin is known to be related to ERCC gene.As a key component of the nucleotide excision repair pathway,ERCC gene is found to regulate DNA repair.ERCC functional differences are mainly related to single nucleotide polymorphisms.The low expression may increase the risk of osteosarcoma,whereas the high expression may increase the resistance to cisplatin.In addition,ERCC gene is related to occurrence and prognosis of osteosarcoma,and is of great significance to the chemotherapy drugs selection.The targeted inhibition of ERCC provides possibility to reduce the resistance of cisplatin.Our review highlights the research progress of ERCC in osteosarcoma and provides relevant concepts for further clinical translational applications.